XNCR - Xencor MD Anderson ink development pact for CD3 bispecific antibody for cancer

Xencor (XNCR) and The University of Texas MD Anderson Cancer Center have entered strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody cancer therapeutics.MD Anderson will identify and develop potential antibodies, and Xencor will apply its XmAb bispecific technology to create the therapeutic candidates. MD Anderson will then conduct and fund all preclinical activities to advance candidates toward clinical studies.Xencor has certain exclusive options to license worldwide rights to develop and commercialize potential candidates. For programs not licensed by Xencor, it will receive a portion of future payments received by MD Anderson. Both the parties are entering into the collaboration with two predetermined, undisclosed antibody candidates.

For further details see:

Xencor, MD Anderson ink development pact for CD3 bispecific antibody for cancer